The authors report two siblings with familial neuroblastoma with a germline R1275Q mutation of the tyrosine kinase domain of ALK. Whole exome sequencing and copy number variation assay were performed to investigate genetic alterations in the two cases. No common somatic mutations or gene polymorphisms related to the tumorigenesis of neuroblastoma were detected. A distinct pattern involving both segmental chromosomal alteration and MYCN amplification was detected. The diversity of biological behavior of familial neuroblastoma harboring a germline ALK mutation may depend on conventional prognostic factors, such as segmental chromosomal alterations and MYCN amplification, rather than additional acquired mutations.
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| INTRODUCTION
Familial neuroblastoma is a rare type of neuroblastoma, with a frequency of 1%-2% of all neuroblastoma cases. The majority of cases are diagnosed in infants, who have multiple primary tumors. 1, 2 Recent studies have shown that the main cause of familial neuroblastoma is a germline ALK mutation that is inherited in an autosomal dominant manner. [1] [2] [3] [4] Several gene polymorphisms are also associated with susceptibility to the development of neuroblastoma. 
| Target sequencing
We amplified the 34 kb region encoding the tyrosine kinase domain of the ALK gene by long PCR. Sequencing library construction was performed according to the Nextera XT sample preparation guide (Illumina, San Diego, CA), using transposase to fragment, and adapter and barcoding sequences were added simultaneously. The pooled and barcoded libraries were subsequently sequenced using the MiSeq sequencing platform with v2 kits. The ALK point mutation was validated by Sanger sequencing.
| Whole exome sequencing and copy number variation assay
Exome capture was performed using the SureSelect Human All Exon V5 (Agilent Technologies, Santa Clara, CA). The sequencing libraries of enriched exome fragments were then subjected to massively parallel Mutation calling was performed through our established pipeline, as previously reported. 6, 7 We employed a sequencing-based method using the data on allele frequencies and sequenced depth of singlenucleotide polymorphisms (SNPs). This technique, referred to as CNACS, is being prepared for publication.
| FISH detection of MYCN amplification and immunohistostaining study of ALK expression
Diagnostic immunohistostaining was performed with Ventana GX System (Roche Diagnostics, K.K., Tokyo, Japan), using anti-ALK antibody (Nichirei bioscience, Tokyo, Japan; clone 5A4; prediluted).
Dual-color FISH analysis was performed using probes for the 
| Targeted RNA sequencing
The library assembled using 40 ng of total RNA isolated from the tumor tissue was subjected to RNA sequencing using TruSight RNA 
| RESULTS
First, we searched for mutation of ALK, which is known to be the main cause of familial neuroblastoma. We identified the heterozygous ALK c.3824G>A (p.Arg1275Gln) mutation in both tumor samples using targeted next generation sequencing. Next, we assessed the germline origin of the mutation and detected the same point mutation in constitutional DNA samples of both cases through Sanger sequencing.
The mutation was also detected in the peripheral blood sample of the mother ( Figure 1A ). We concluded that these two cases were familial neuroblastoma, harboring a heterozygous germline R1275Q mutation of ALK, which has been confirmed as a driver mutation in both sporadic and familial neuroblastoma. deletion, and 19p deletion were detected in case 2 ( Figure 2A ). FISH detected MYCN amplification in case 2 ( Figure 2B ). In addition, we conducted targeted RNA sequencing using the two tumor samples. A differential expression assay extracted 6 genes, the expression of which were significantly different between the two cases ( Figure 2C ).
| DISCUSSION
In this study, we identified ALK point mutations in three affected members within the same family. We performed whole exome sequencing, copy number variation assay, and targeted RNA sequencing using two neuroblastoma samples to identify genetic alterations affecting the distinct clinical phenotype of familial neuroblastoma.
Previous large-scale genetic studies have indicated that the total number of somatic mutations in sporadic neuroblastoma is extremely low, compared with those in adult cancers. 8, 13 As expected, no common somatic mutations known to be related to the development of neuroblastoma were detected by whole exome sequencing (Supporting Information, Table S1 ). Recent genomewide association studies have revealed gene polymorphisms associated with the tumorigenesis of neuroblastoma. 5 Although, no SNPs related to neuroblastoma were detected in the two samples from the siblings, the copy number variation assay demonstrated a distinct pattern of segmental chromosome abnormality in the two familial neuroblastoma cases (Supporting Information, Table S2 ).
Case 1 showed a gain of several chromosomes and an increased DNA index with no MYCN amplification, which are frequently seen in low-risk neuroblastoma. 14, 15 A good clinical response to chemotherapy was observed in case 1. In contrast, we identified segmental chromosomal aberrations, such as 11q deletion, gain of 17q, and MYCN amplification in case 2, which are frequently detected in aggressive neuroblastoma with a poor prognosis. [16] [17] [18] Differential expression assay extracted genes such as BDNF, SOX2, and ERBB3, which are related to aggressive neuroblastoma or ganglioneurolastoma, [10] [11] [12] were highly expressed only in case 2 ( Figure 2C ). A poor response to intensive chemotherapy was observed in case 2. A recent clinical trial showed that neuroblastoma harboring ALK mutation responded well to targeted ALKinhibition therapy. 19 Therefore, crizotinib may be considered as an attractive treatment option for familial neuroblastoma with ALK mutation, instead of intensive chemotherapy.
In this family, the mother developed a benign solid tumor. Low penetrance of a germline mutation of ALK contributes to various phenotypes within a family and genetic modifiers, such as SNPs and epigenetic alteration, affect the tumorigenesis of neuroblastoma. 3, 5, 20 However, it is still unknown why only the present two cases developed neuroblastoma and which genes affected by the segmental chromosomal aberration played a significant role. Therefore, further investigation is needed to uncover the mechanism of tumorigenesis in familial neuroblastoma.
In summary, our analysis demonstrated that segmental chromosomal aberrations, including MYCN amplification, affected the clinical phenotype of familial neuroblastoma harboring ALK germline mutation, rather than acquired mutations.
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